Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients ≥6 years to <12 years of age, with severe atopic dermatitis

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients ≥6 years to <12 years of age, with severe atopic dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY AD PEDS
  • Sponsors Regeneron Pharmaceuticals; Sanofi

    • Most Recent Events

    • 26 Feb 2024 Results of pooled analysis of LIBERTY AD PRESCHOOL,LIBERTY AD PEDS , LIBERTYAD ADOL , LIBERTY AD SOLO1,LIBERTYADSOLO2 reporting serum CCL17/TARC (human TARC Quantikine ELISA kit; R&D Systems) levels from patients with moderate-to-severe or severe AD, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 10 Jun 2023 Post-hoc (n=304) results published in the American Journal of Clinical Dermatology.
    • 30 Apr 2023 Results published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top